Where I see patients (2)
My reviews
Selected research
-
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
The oncologist
-
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
JCO precision oncology
-
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer.
Prostate cancer and prostatic diseases
Clinical trials
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate C...
If two or more patients in a cohort experience a dose-limiting toxicity (DLT), then the maximum tolerated dose (MTD)has been exceeded. The previous dose level will be considered the MTD and the recommended phase 2 dose. Per Invest...
Recruiting
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Canc...
The RP2D is the last dose cohort at which no more than one instance of a dose limiting toxicity (DLT) is observed among 6 participants treated. If the maximum tolerated dose (MTD) cannot be determined due to lack of DLT during the...
Recruiting
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
The proportion of participants who have a best overall response (BOR) based on complete response (CR) or partial response (PR). The BOR for each participant is the best response (radiographically documented and measurable disease ...
Recruiting
4.9